89660-20-8

Upstream product

• 33742-70-0 6-chloro-N-methyl-3-nitropyridin-2-amine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 89660-14-0 6-chloro-N²-methylpyridine-2,3-diamine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 40851-98-7 5-chloroimidazo<4,5-b>pyridin-2-one 
• 74-88-4 methyl iodide 

Downstream Products

• 1352422-16-2 1-(2,2-dimethylpropyl)-3-methyl-5-(3-methylphenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352422-14-0 1-(2,2-dimethylpropyl)-3-methyl-5-(2-methylphenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352422-09-3 4-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]benzonitrile 
• 1352422-06-0 3-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]benzonitrile 
• 1352421-95-4 2-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]benzonitrile 
• 1352421-94-3 1-(2,2-dimethylpropyl)-3-methyl-5-phenyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352421-24-9 1-(2,2-dimethylpropyl)-5-[5-(2-hydroxypropan-2-yl)-2-methylphenyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352423-88-1 2-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]-4-(1-hydroxy-1-methylethyl)benzonitrile 
• 1352426-59-5 1-(2,2-dimethylpropyl)-5-[5-(hydroxymethyl)-2-methylphenyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352421-89-6 1-(2,2-dimethylpropyl)-5-[3-[hydroxymethyl]phenyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352421-25-0 1-(2,2-dimethylpropyl)-3-methyl-5-[4-(methylsulfonyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352422-13-9 1-(2,2-dimethylpropyl)-5-(2-methoxyphenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352422-08-2 1-(2,2-dimethylpropyl)-5-(2-fluorophenyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1352422-10-6 1-(2,2-dimethylpropyl)-3-methyl-5-(4-methylphenyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 

Relevant academic research and scientific papers

Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis

Optimization of a benzimidazolone template for potency and physical properties revealed 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as a key template on which to develop a new series of mGlu2 positive allosteric modulators (PAMs). Systematic invest

Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI

Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibited strong in vitro activity and attractive pharmacokinetic (PK) properties. Hypothesis-driven target design identified compound 21 as a potent, highly selective, orally bioavailable mGluR2 PAM, which addressed a CYP time-dependent inhibition (TDI) liability of 18, while maintaining excellent drug-like properties with robust in vivo activity in a clinically validated model of antipsychotic potential.

IMIDAZOPYRIDIN-2-ONE DERIVATIVES

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

POSITIVE ALLOSTERIC MODULATORS OF MGLUR2

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.

IMIDAZOPYRIDIN-2-ONE DERIVATIVES

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Compounds with antiulcer and antisecretory activity. III. N-substituted imidazolones condensed with nitrogen-containing heteroaromatic rings

The syntheses of imidazo[4,5-b]pyridin-2-ones and -thiones, imidazo [4,5-c]pyridin-2-ones and 7,9-dihydro-8H-purin-8-ones arylated (or heteroarylated) at an imidazolone nitrogen are reported. Only some compounds of the first series have marked antisecreto